AstraZeneca PLC (AZN)
NASDAQ: AZN · IEX Real-Time Price · USD
76.41
+0.53 (0.70%)
At close: May 1, 2024, 4:00 PM
76.62
+0.21 (0.27%)
Pre-market: May 2, 2024, 5:04 AM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $47.61B in the twelve months ending March 31, 2024, with 8.60% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $12.68B with 16.55% year-over-year growth. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
$47.61B
Revenue Growth
+8.60%
P/S Ratio
4.97
Revenue / Employee
$529,600
Employees
89,900
Market Cap
236.86B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
Dec 31, 2005 | 23.95B | 2.52B | 11.78% |
Dec 31, 2004 | 21.43B | 2.58B | 13.67% |
Dec 31, 2003 | 18.85B | 1.01B | 5.65% |
Dec 31, 2002 | 17.84B | - | - |
Dec 31, 2001 | - | - | - |
Dec 31, 2000 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
Novo Nordisk | 33.39B |
AZN News
- 22 hours ago - AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio - Business Wire
- 1 day ago - FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How - Forbes
- 1 day ago - FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition' - Market Watch
- 2 days ago - 'A shadow of what I was': Dad who suffered brain injury days after getting COVID jab sues AstraZeneca - Skynews
- 2 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow - Business Wire
- 3 days ago - ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial - Business Wire
- 6 days ago - AstraZeneca Gets a Boost From Sales of Its Cancer Drugs - Investopedia
- 6 days ago - AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - PRNewsWire